Accutane (Isotretinoin) and Apixaban Interaction: What Patients and Prescribers Need to Know

Does isotretinoin change apixaban levels?

Apixaban is cleared mainly through CYP3A4 metabolism, with P-gp and BCRP transport; about 27% of its clearance is renal [3]. The Eliquis label advises avoiding combined P-glycoprotein and strong CYP3A4 inducers, including rifampin, carbamazepine, phenytoin and St. John's wort, because exposure falls and the risk of stroke and other thromboembolic events rises [3].

The human number closest to that rule comes from rifampin: in 20 healthy participants, rifampin 600 mg daily lowered oral apixaban AUC by 54% and absolute bioavailability from 49% to 39% [1]. Inhibitors move exposure the other way. In two studies of 18 healthy subjects each, ketoconazole raised apixaban AUC by 99% and diltiazem raised it by 40% [4].

The Accutane label does not list apixaban as an interaction. It discusses vitamin A, tetracyclines, hormonal contraceptives, St. John's wort, phenytoin and systemic corticosteroids [2].

The only statement in the Accutane label about isotretinoin's effect on a CYP enzyme concerns CYP2C9: an in vitro finding that neither isotretinoin nor its metabolites induce or inhibit CYP2C9, plus a study in seven healthy volunteers in which isotretinoin did not alter phenytoin pharmacokinetics [2]. That is a statement about CYP2C9, not about CYP3A4 or P-glycoprotein, the two pathways the apixaban inducer rule concerns.

In the other direction, at therapeutic exposure apixaban does not meaningfully inhibit or induce major CYP enzymes in vitro [3]. Isotretinoin is metabolized in vitro by CYP2C8, 2C9, 3A4 and 2B6 [2].

Bleeding: what each label says

Eliquis carries warnings about serious, potentially fatal bleeding and about increased thrombotic risk after premature discontinuation of an oral anticoagulant [3]. The label says drugs affecting hemostasis add to bleeding risk: aspirin and other antiplatelets, other anticoagulants, heparin, thrombolytics, SSRIs, SNRIs and NSAIDs [3]. Isotretinoin is not on that list.

The isotretinoin labeling lists epistaxis, dry nose, skin fragility, bruising, dry skin and dry lips among adverse reactions [2]. The Absorica and Absorica LD label, a different isotretinoin product, puts epistaxis among the most common reactions, at 5% or higher, and lists thrombocytopenia and increased platelet counts under hematologic reactions [5]. Neither label addresses bleeding risk with the combination.

What the labels say to watch for

For adults, the Eliquis label identifies andexanet alfa as a specific reversal agent and states that apixaban's effect persists for at least 24 hours after the last dose [3]. Protamine sulfate and vitamin K are not expected to affect its activity, and unlike warfarin there are no vitamin K diet rules and no INR targets [3]. Eliquis is contraindicated in patients with active pathological bleeding or severe hypersensitivity to the drug [3].

On the isotretinoin side, the Accutane label says blood lipid determinations should be performed before treatment and then at intervals until the lipid response is established, which usually occurs within 4 weeks [2]. The Absorica label's warnings cover psychiatric disorders, intracranial hypertension, serious skin reactions, pancreatitis, lipid abnormalities, hearing impairment, hepatotoxicity, inflammatory bowel disease, musculoskeletal abnormalities and ocular abnormalities [5].